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Background. Genotypic antiretroviral resistance testing (GRT) in HIV infection with drug resistant virus is recommended to
optimize antiretroviral therapy, in particular in patients with virological failure. We estimated the clinical effect, cost and cost-
effectiveness of using GRT as compared to expert opinion in patients with antiretroviral treatment failure. Methods. We
developed a mathematical model of HIV disease to describe disease progression in HIV-infected patients with treatment failure
and compared the incremental impact of GRT versus expert opinion to guide antiretroviral therapy. The analysis was
conducted from the health care (discount rate 4%) and societal (discount rate 2%) perspective. Outcome measures included
life-expectancy, quality-adjusted life-expectancy, health care costs, productivity costs and cost-effectiveness in US Dollars per
quality-adjusted life-year (QALY) gained. Clinical and economic data were extracted from the large Swiss HIV Cohort Study and
clinical trials. Results. Patients whose treatment was optimized with GRT versus expert opinion had an increase in discounted
life-expectancy and quality-adjusted life-expectancy of three and two weeks, respectively. Health care costs with and without
GRT were $US 421,000 and $US 419,000, leading to an incremental cost-effectiveness ratio of $US 35,000 per QALY gained. In
the analysis from the societal perspective, GRT versus expert opinion led to an increase in discounted life-expectancy and
quality-adjusted life-expectancy of three and four weeks, respectively. Health care costs with and without GRT were $US
551,000 and $US 549,000, respectively. When productivity changes were included in the analysis, GRT was cost-saving.
Conclusions. GRT for treatment optimization in HIV-infected patients with treatment failure is a cost-effective use of scarce
health care resources and beneficial to the society at large.
Citation: Sendi P, Gu ¨nthard HF, Simcock M, Ledergerber B, Schu ¨pbach J, et al (2007) Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing
in HIV-Infected Patients with Treatment Failure. PLoS ONE 2(1): e173. doi:10.1371/journal.pone.0000173
INTRODUCTION
The advent of potent antiretroviral therapies (ART) a decade ago
has led to a substantial decline of morbidity and mortality in HIV
infected patients [1–3]. Since then many new compounds and
drug classes for the treatment of HIV infection have been
developed that have substantially increased the complexity of
HIV patient care [4]. The emergence of resistant mutations to
antiretroviral drug compounds and classes, in addition, may
jeopardize the success of HIV treatment and accelerate disease
progression [4–6]. Genotypic antiretroviral resistance testing
(GRT) helps to distinguish between antiretroviral drugs to which
HIV has become resistant and compounds that effectively suppress
viral replication [7–9].
It has been documented in randomized controlled trials that
GRT based treatment optimization leads to a higher viral load
reduction than standard care alone in treatment-experienced
patients [8,10,11]. Published clinical guidelines now recommend
GRT in patients with antiretroviral treatment failure or in recently
infected patients who may have acquired drug-resistant virus
[12–14]. The cost of GRT guided therapy, however, is substantial
(e.g., $US 625 per test in Switzerland and $US 400–500 in the
USA) [15–17], which has prompted a debate about the appropr-
iate use and financing of antiretroviral resistance testing in Europe
and the USA [15,17]. Health insurance companies may still be
reluctant to finance GRT although it’s cost-effectiveness has been
documented in a few countries.
Early and more recent cost-effectiveness studies suggested that
antiretroviral treatment optimization using GRT is cost-effective
[17–19]. However, these studies did not specifically investigate
job productivity changes, did not include the results of more
recent long-term studies of antiretroviral resistance testing, and
did not make use of the same large homogenous database on
HIV disease to describe both clinical and economic outcomes.
We developed a comprehensive model of HIV disease using the
Swiss HIV Cohort Study (SHCS) database to describe disease
progression [20]. We included resistance testing data from long-
term studies and several clinical trials, and used data from
patients enrolled in the SHCS to estimate the clinical effect, cost
and cost-effectiveness of treatment optimization using GRT as
compared to expert opinion in patients with antiretroviral
treatment failure.
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Study design
We developed a mathematical model of HIV disease to assess the
incremental impact of antiretroviral therapy guided by genotypic
antiretroviral resistance testing versus expert opinion alone in
patients presenting with treatment failure defined as i) a viral log
reduction of ,1 log HIV RNA copies/ml during the first six
months after initiation of antiretroviral therapy (ART), ii) a viral
load increase of .1 log HIV RNA copies/ml within two months
of ART, or iii) two consecutive viral load assessments .200 cop-
ies/ml after reaching undetectable plasma HIV RNA levels
(,50 copies/ml) [21]. Outcome measures included life-years,
quality-adjusted life-years (QALYs), health care costs and pro-
ductivity costs over a patient’s lifetime. Model parameters were
mainly derived from patients enrolled in the Swiss HIV Cohort
Study (SHCS), one of the largest cohort studies on HIV disease
with over 14’000 patients enrolled to date [20].The analyses were
conducted from the health care as well as societal perspective and
costs and effects were discounted at an annual rate of 4% and 2%,
respectively. The discount rate from the societal perspective
reflects the current interest rate in Swiss government bonds
whereas the discount rate from the health care perspective reflects
the rate typically used by Swiss social health insurers [22,23].
Disease model
A state transition model of HIV disease with mutually exclusive
health states was developed to describe the course of HIV disease
after antiretroviral treatment failure, the starting state of patients
entering the model [24,25]. The failing treatment schedule is then
either maintained or replaced by another regimen, based on
expert opinion alone or with information available from genotypic
antiretroviral resistance testing. Reasons for maintaining the
failing treatment regimen may include the lack of more effective
treatment options, patients refusing the required number of pills
per day, or stable CD4 cell count despite virological failure [21].
Patients may reach virological suppression (,50 copies/ml) or
have a detectable viral load during the subsequent two years with
the likelihood of virological suppression being modeled as
a function of the level of resistance of the HIV to the prescribed
drug regimen [21]. To model the long-term impact of treatment
optimization following genotypic antiretroviral resistance testing
health states in patients without AIDS in the third year and
thereafter were further stratified according to CD4 cell count
(strata: 0–200 cells/mm
3, 201–500 cells/mm
3, .500 cells/mm
3)
and viral load (,1000 copies/ml, $1000 copies/ml), and in
patients who experienced an AIDS-indicator disease by CD4 cell
count only (strata: 0–200 cells/mm
3, 201–500 cells/mm
3,
.500 cells/mm
3). Patients are always at risk of dying due to an
HIV-related or unrelated cause and were modeled until death.
The disease model was populated with data extracted from the
SHCS; the starting age of patients is 33 years, the average age of
patients enrolled in the SHCS, and 80% of patients are male
[20,21].
Antiretroviral resistance testing
The probability of maintaining the failing antiretroviral regimen
or switching to a new regimen with or without information
available from GRT was derived from Haupts et al. [21], a study
within the SHCS that assessed the impact of GRT on the selection
of salvage regimens in patients presenting with treatment failure
(Table 1). The prescribed drug regimen may then either contain
no drugs to which a resistant mutation is reported or may contain
one or more drugs to which the virus is resistant (Table 1). The
probability of achieving viral suppression was then conditioned on
the level of viral resistance of the virus to the final chosen drug
regimen as defined in Haupts et al. [21]. Patients were repeatedly
tested for the presence of HIV drug resistance mutations during
the two-year follow up period, if necessary, to improve the
likelihood of viral suppression [21]; patient management,
adherence and virological outcomes therefore reflect a real-world
setting. The distribution of patients across CD4 cell counts and
Table 1. Transition probability matrix for achieving viral suppression, stratified by resistance score of the drug regimen
..................................................................................................................................................
no resistance to drug regimen
1 low resistance to drug regimen
2
considerable resistance to drug
regimen
3
Health States
Virological
suppression
(,50 copies/ml)
Detectable
viral load
($50 copies/ml)
Virological
suppression
(,50 copies/ml)
Detectable
viral load
($50 copies/ml)
Virological
suppression
(,50 copies/ml)
Detectable
viral load
($50 copies/ml)
Consecutive 6
month cycles
Transition probabilities
Virological
suppression
(,50 copies/ml)
Month 0–6
Month 7–12 0.68 0.32 0.89 0.11 0.83 0.17
Month 13–18 0.93 0.07 0.99 0.01 0.92 0.08
Month 19–24 0.93 0.07 0.94 0.06 0.99 0.01
Detectable
Viral Load
($50 copies/ml)
Month 0–6 0.63 0.37 0.46 0.54 0.20 0.80
Month 7–12 0.36 0.64 0.37 0.63 0.12 0.88
Month 13–18 0.46 0.54 0.15 0.85 0.08 0.92
Month 19–24 0.50 0.50 0.01 0.99 0.17 0.83
1corresponds to a resistance score of 1 as defined in Haupts et al. [21]
2corresponds to a resistance score between 1 and 2 as defined in Haupts et al. [21]
3corresponds to a resistance score of $2 as defined in Haupts et al. [21]
doi:10.1371/journal.pone.0000173.t001
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PLoS ONE | www.plosone.org 2 January 2007 | Issue 1 | e173viral load at the end of the two-year follow-up period was used to
populate the model for projecting long-term costs and clinical
outcomes over a patient’s lifetime. In this subsequent model, the
relative risk of experiencing treatment failure when expert opinion
alone was used versus GRT in virologically suppressed patients
was derived from published randomized controlled trials
[8,10,11,26,27].
HIV disease progression
HIV disease progression was modeled by means of a transition
probability matrix derived from the SHCS using the dataset from
the period 1996–2004 before GRT became widely available. The
probability of transitions to a health state with a viral load above or
below 1000 copies/ml, a different CD4 cell stratum, the risk of
developing an AIDS-indicator disease and dying was extracted
from the SHCS database by pooling observations from patients on
highly active antiretroviral therapy over consecutive six-month
periods [28–30], which reflects the average period between patient
visits in the SHCS (Table S1). The risk of dying from causes not
related to HIV disease was derived from Swiss life tables (www.
statistik.admin.ch).
Quality of life
HIV disease may not only affect survival but may also substantially
affect the patient’s wellbeing [31]. In order to calculate quality-
adjusted life-years (QALYs) the length of time a patient spent in
a specific health state was adjusted for the quality (i.e., utility) of
that state on a scale ranging from zero (death) to one (best possible
health state). The utility values used in our study are derived from
a study on quality of life in patients enrolled in SHCS [32] by
transforming health state values assessed on a visual analogue scale
into standard gamble utilities using methods as described in detail
elsewhere [33]. We used regression analysis methods to derive the
utilities for the different health states shown in Table 2. The
disutility of experiencing an AIDS-indicator disease was derived
from a meta-analysis of utility estimates in HIV-infected patients
(Table 2) [31]. Since a proportion of patients may partially include
the effects of ill-health on income in health state valuation [34–36],
utilities were adjusted by increasing their value by 4.5%, as derived
from Sendi and Brouwer [35]. This approach was chosen to
exclude any income effects of HIV disease in QALY estimation
since productivity costs are already included in monetary terms
(Table 2).
Costs
In the analysis from the health care perspective we only included
costs due to health care resource consumption (Table 2). We used
microcosting [23] as reported in detail previously to assess the costs
associated with antiretroviral therapy, drugs for the prevention of
opportunistic diseases and other drugs such as antihypertensive,
lipid-lowering or antidiabetic agents [15,29]. Ambulatory costs
included the costs associated with a doctor’s visit, CD4 cell count
and viral load measurements, blood chemistry, blood count and
other diagnostic procedures such as radiological, cardiovascular
and endoscopic examinations [15,29]. The cost of GRT was $US
625 [15]. To approximate in-patient costs we used charges to
Swiss health insurers for patient who stayed a minimum of one
night in a hospital [15]. All costs were expressed in 2005 $US
using the Swiss consumer price index for health care and the
exchange rate of July 1
st, 2005 ($US 100=CHF 128, www.
oanada.com).
With the advent of potent antiretroviral therapy HIV infection
has become a chronic disease, predominantly in young patients in
the working age [3]. It is therefore important to include in the
analysis from the societal perspective the impact of GRT-based
antiretroviral treatment optimization on the patients’ ability to
work and hence productivity [37]. The number of hours a patient
worked was recorded during each 6-month visit where SHCS
enrollees are regularly examined [29]. We therefore extracted the
number of hours a patient worked in each health state as defined
above from the SHCS database and attached an average Swiss
wage rate of $US 20 per hour (www.statistik.admin.ch) to estimate
productivity changes over a patient’s simulated lifetime (Table 2).
The difference in productivity between patients whose treatment
were optimized with GRT versus expert opinion only was then
subtracted from the health care costs associated with GRT
[38,39].
Sensitivity analysis
We used probabilistic sensitivity analysis to assess the uncertainty
around the cost and effect estimates as recommended by most
recent guidelines [23,40,41].
Hereby a distribution is ascribed to each model input parameter
using Bayesian methodology and noninfomative prior distributions
[42–44]. We used normal distributions for cost and quality of life
estimates with the corresponding standard error to model
uncertainty associated with the mean input parameters, and we
used a log-normal distribution for modeling the uncertainty
associated with the relative risk of a treatment failure without
GRT [44]. The uncertainty around count variables were modeled
by means of a Dirichlet distribution, the conjugate distribution of
the multinomial distribution for modeling the probability of events
[45]. We used Monte Carlo simulation to estimate the uncertainty
around the point estimate of incremental costs and effects of GRT
versus expert opinion by sampling 5000 times from all input
distributions and then recalculating the model using specialized
software (TreeAge Pro 2005, TreeAge Software Inc., Williams-
town, USA). The joint distribution of the resulting incremental
costs and effects in our model were then summarized in terms of
cost-effectiveness acceptability curves that describe the probability
that the intervention is cost-effective as a function of the maximum
willingness to pay per QALY gained [46,47].
RESULTS
Health care perspective
The main results of our analysis using the base case input
parameters are shown in Table 3. Patients whose treatment was
optimized with information available from GRT versus expert
opinion had an increase in undiscounted life-expectancy and
quality-adjusted life-expectancy of 2 and 6 weeks, respectively.
When a 4% discount rate was used these figures were 3 and 2
weeks (Table 3). Undiscounted health care costs with and without
GRT were $US 763’000 and $US 761’000, respectively, and $US
421’000 and 419’000 when a 4% discount rate was used. This
corresponds to an expected cost-effectiveness ratio of $US 35’000
per QALY gained (Table 4).
The point estimate and 95% credible intervals of incremental
costs and effects are shown in Figure 1A. The probability that
GRT will lead to a better health outcome is 89% and there is
a 95% probability that incremental quality-adjusted life-months
(QALMs) lie between 20.4 and 1.6. The probability that GRT
will increase health care costs is 100% with the additional costs
lying between $US 800 and $US 2900 with 95% probability.
Summarizing the uncertainty around cost and effect estimates in
terms of cost-effectiveness acceptability curves, i.e. the probability
that the intervention is cost-effective for all possible willingness to
HIV Resistance Testing
PLoS ONE | www.plosone.org 3 January 2007 | Issue 1 | e173Table 2. Main input variables of the cost-effectiveness model
..................................................................................................................................................
Variable Point estimate Distribution
Parameters of
distribution
1 Reference
Resistance testing Probability
Change/maintain regimen after GRT 0.67/0.33 Dirichlet (90;44) 21
Change/maintain regimen without GRT 0.97/0.03 Dirichlet (142;5) 21
No/low/considerable resistance
2 when treatment is changed after GRT 0.28/0.42/0.30 Dirichlet (26;39;28) 21
No/low/considerable resistance
2 when treatment is maintained after GRT 0.21/0.05/0.74 Dirichlet (8;2;28) 21
No/low/considerable resistance
2 when treatment is changed without GRT 0.26/0.33/0.41 Dirichlet (38;48;58) 21
No/low/considerable resistance
2 when treatment is maintained without GRT 0.14/0.14/0.72 Dirichlet (1;1;5) 21
RR treatment failure without GRT 1,27 Lognormal (0.23;0.11) 8,10,11,26,27
Quality of life Health state utility Mean/SD
Undetectable viral load, first 2 years 0,790 Normal (0,790; 0,006) 32
Detectable viral load, first 2 years 0,755 Normal (0,755; 0,010) 32
No AIDS, CD4 0–200 cells/mm
3 0,739 Normal (0,739; 0,020) 32
No AIDS, CD4 201–500 cells/mm
3 0,780 Normal (0,780; 0,010) 32
No AIDS, CD4 CD4 $500 cells/mm
3 0,801 Normal (0,801; 0,009) 32
Disutilty of a detectable viral load after year 2 0,035 Normal (0,035; 0,012) 32
Disutility of an AIDS-indicator disease 0,233 Normal (0,233; 0,058) 32
Utility adjustment for the exclusion of income effects 1,045 Normal (1,045; 0,043) 35
Costs $US per 6 months Mean/SD
Undetectable viral load, first 2 years 18’427 Normal (18’427, 857) 15,21
Detectable viral load, first 2 years 16’870 Normal (16’870, 636) 15,21
No AIDS, CD4 0–200 cells/mm
3, ,1000 HIV RNA copies/ml 23’504 Normal (23504, 2835) 15,21
No AIDS, CD4 0–200 cells/mm
3, $1000 HIV RNA copies/ml 19’264 Normal (19’264, 1300) 15,21
No AIDS, CD4 201–500 cells/mm
3, ,1000 HIV RNA copies/ml 16’519 Normal (16’519, 545) 15,21
No AIDS, CD4 201–500 cells/mm
3, $1000 HIV RNA copies/ml 14’898 Normal (14’898, 693) 15,21
No AIDS, CD4 $500 cells/mm
3, ,1000 HIV RNA copies/ml 17’207 Normal (17’207, 1245) 15,21
No AIDS, CD4 $500 cells/mm
3, $1000 HIV RNA copies/ml 15’127 Normal (15’127, 1124) 15,21
AIDS, CD4 0–200 cells/mm
3 44’736 Normal (44736, 710) 29
AIDS, CD4 201–500 cells/mm
3 29’402 Normal (29’402, 466) 29
AIDS, CD4 $500 cells/mm
3 17’207 Normal (17’207, 1245) assumption
Productivity Hours per month Mean/SD
Undetectable viral load, first 2 years 96 Normal (96, 5) SHCS
Detectable viral load, first 2 years 86 Normal (86, 5) SHCS
No AIDS, CD4 0–200 cells/mm
3, ,1000 HIV RNA copies/ml 81 Normal (81, 9) SHCS
No AIDS, CD4 0–200 cells/mm
3, $1000 HIV RNA copies/ml 80 Normal (80,7) SHCS
No AIDS, CD4 201–500 cells/mm
3, ,1000 HIV RNA copies/ml 100 Normal (100, 6) SHCS
No AIDS, CD4 201–500 cells/mm
3, $1000 HIV RNA copies/ml 96 Normal (96, 7) SHCS
No AIDS, CD4 $500 cells/mm
3, ,1000 HIV RNA copies/ml 100 Normal (100,9) SHCS
No AIDS, CD4 $500 cells/mm
3, $1000 HIV RNA copies/ml 74 Normal (74, 15) SHCS
AIDS, CD4 0–200 cells/mm
3 55 Normal (55, 5) SHCS
AIDS, CD4 201–500 cells/mm
3 66 Normal (66, 9) SHCS
AIDS, CD4 $500 cells/mm
3 68 Normal (68, 25) SHCS
Hourly wage rate in $US 20 Normal (20, 5) www.admin.
statistik.ch
1The Dirichlet distribution is a multivariate generalization of the Beta distribution with pj~
xj
Pk
i~1 xi
where 0#pj#1 and
Xk
i~1 pi~1 with parameters a1,
a2,…,b=1
2see footnote of Table 1 for definition
doi:10.1371/journal.pone.0000173.t002
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
HIV Resistance Testing
PLoS ONE | www.plosone.org 4 January 2007 | Issue 1 | e173pay per QALY gained, we see that at a willingness to pay of $US
35’000 or more per QALY gained GRT is the preferred treatment
option (Figure 2A).
Societal perspective
The main results of our analysis from the societal perspective, i.e.
including the effects of ill-health on income in monetary terms, are
shown in Table 3. Patients whose treatment was optimized with
information available from GRT versus expert opinion had an
increase in life-expectancy and quality-adjusted life-expectancy of
3 and 4 weeks when a 2% discount rate was used (Table 3).
Discounted health care costs with and without GRT were $US
551’000 and $US 549’000, respectively (Table 3). Patients who did
not receive GRT, however, had an expected discounted income of
$US 399’000 versus $US 401’000 when treatment was optimized
with help of GRT (Table 3). This gain in productivity more than
offsets the additional health care costs due to GRT (Table 3 and 4)
and GRT is therefore a dominant strategy from the societal
perspective.
The point estimate and 95% credible intervals of incremental
costs and effects are shown in Figure 1B. The probability that
GRT will lead to a better health outcome is 91% and there is
a 95% probability that incremental QALMs lie between 20.4 and
2.3. The probability that GRT will increase health care costs is
52% with the incremental costs lying between $US 23800 and
$US 1900 with 95% probability. Since the societal costs including
productivity changes are skewed towards negative values, the point
estimate of incremental costs leads to cost savings (Table 3)
whereas the probability of achieving cost savings with GRT com-
pared to expert opinion is slightly lower than 50%. Summarizing
the uncertainty around cost and effect estimates in terms of cost-
effectiveness acceptability curves, i.e. the probability that the
intervention is cost-effective for all possible willingness to pay per
QALY gained, we see that at a willingness to pay of $US 850 or
more per QALY gained GRT is the preferred treatment option
(Figure 2B). Using the widely mentioned societal threshold of $US
50’000 per QALY, GRT is cost-effective with a probability of 88%.
DISCUSSION
We found that GRT increases projected life-expectancy and
quality-adjusted life-expectancy by 2 and 6 weeks, respectively.
This increase in quality-adjusted survival is clinically meaningful
and comparable to the benefit of elective surgery in patients with
symptomatic gallstones (gain in life-expectancy 1.7 months) or the
benefit of Hepatitis B vaccination in newborn babies whose
mothers have Hepatitis B (gain in life-expectancy 2 weeks) [48].
GRT is a dominant strategy from the societal perspective as the
additional health care costs incurred by adding GRT to the
treatment plan are more than offset by the increase in job
productivity in HIV infected patients. When we included the
uncertainty with respect to the input parameters of the model in
the analysis, GRT has an 88% probability of being cost-effective
when we used $US 50’000 per QALY gained as a threshold to
determine whether an intervention represents value for money.
However, when only health care costs are considered, the cost-
effectiveness ratio of GRT is $US 35’000 per QALY gained,
which is similar to the cost-effectiveness ratio of implantable
cardioverter-defibrillators ($US 35’000 per QALY gained) [49]
and more cost-effective than other HIV treatment efforts such as
antibiotic prophylaxis against M. avium complex infection in
patients with AIDS ($US 80’000 per QALY gained) [42] and non-
HIV interventions such as the use of drug-eluting stents in patients
with coronary stenosis ($US 80’000 per QALY gained) [50].
In a previous study we have shown that GRT reduces health
care costs over a two-year follow-up period due to the reduction
of ambulatory and in-patient costs and a reduced consumption
of non-HIV medication [15]. When compared to treatment
optimization based on expert opinion, GRT increases overall
health care costs by $US 1800 only (Table 4). The inclusion of
productivity costs in our analysis, however, has a major impact
on the results because with newer antiretroviral therapy HIV
Table 3. Health care costs, productivity, life-years and quality-adjusted life-years (QALY) with and without genotypic resistance
testing (GRT)
..................................................................................................................................................
undiscounted
discount rate 2%
Societal perspective
discount rate 4%
Health care perspective
GRT Expert Opinion GRT Expert Opinion GRT Expert Opinion
Life-years 25,72 25,68 19,40 19,35 15,49 15,43
QALYs 19,34 19,22 14,27 14,19 11,12 11,07
Health care costs* 762900 760700 550500 548600 420900 419200
Productivity* 543600 540300 400600 398500 311600 310200
*expressed in 2005 $US ($US 100 correspond to CHF 128 as per July 1
st, 2005, www.oanada.com), rounded to the nearest 100
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Table 4. Health care costs and societal costs per quality-adjusted life-year (QALY) gained of genotypic resistance testing (GRT)
versus expert opinion
..................................................................................................................................................
GRT vs Expert opinion Incremental costs* Incremental QALY Cost-effectiveness ratio ($US per QALY gained)
Health care perspective
Discounted at 4% 1800 0,05 35000
Societal perspective
Discounted at 2% 2200 0,08 dominant
*expressed in 2005 $US ($US 100 correspond to CHF 128 as per July 1
st, 2005, www.oanada.com), rounded to the nearest 100
doi:10.1371/journal.pone.0000173.t004
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PLoS ONE | www.plosone.org 5 January 2007 | Issue 1 | e173infection has become a chronic disease and patients, mostly adults
in their working age, retain their ability to work [29,37]. This is
particularly true in countries with a low unemployment rate such
as Switzerland.
In the present paper we also considered the most recent
methodological developments with respect to the inclusion of
productivity costs in economic evaluation to avoid a biased cost-
effectiveness ratio [34,35]. Since current evidence suggests that
respondents or patients do not consistently include the effects of ill-
health on income in health state valuation, omitting productivity
costs in monetary terms from the analysis may lead to an
underestimation of job productivity changes [35]. On the other
hand, including productivity costs without adjusting utility weights
in cost-effectiveness analysis can lead to an overestimation of job
productivity changes [35]. We therefore included productivity
costs in monetary terms and used adjusted utility weights to avoid
double-counting of productivity changes.
Our study has several limitations. We used a mathematical
model to approximate the real-world and project long-term costs
and outcomes of GRT. However, we used best available evidence
from one of the largest cohort studies on HIV disease to reflect
a real-world setting [20]. The gain in (quality-adjusted) life-
expectancy is slightly more conservative than those reported by
other groups, which range from 1.3 months to 1.4 years [17,18].
These differences could be due to differences in modeling natural
disease history. However, our estimate is in line with the conserva-
tive scenario of Corzillius et al. [18] and supports the modeling
process validity of both research groups [51]. Furthermore, we did
not explicitly model patient compliance, which has been shown to
substantially influence results [52]. Patient compliance, however, is
already incorporated in the estimation of transition probabilities
derived from the SHCS. In addition, resistance accumulation
reduces viral fitness and may maintain CD4 cell counts over
prolonged periods associated with clinical non-progression for
some time. We explicitly modeled the possibility of maintaining
the failing antiretroviral regimen, which reduces the short-term
chance of viral suppression but may prevent the development of
multi-resistant virus and hence preserves future drug options [53].
Our study has been conducted in Switzerland where health
insurance is compulsory by law for all patients. However, our
Figure 1. Difference in costs and effects between genotypic
antiretroviral resistance testing and expert opinion for treatment
optimization in HIV infected patients with treatment failure from the
health care (A) and societal (B) perspective. Bars indicate the 95%
credible intervals for incremental costs and effects. One quality-
adjusted life-year corresponds to 12 quality-adjusted life-months. The
bars cross each other at the median. The mean point estimate of the
bivariate distribution of incremental costs and effects is indicated as
a dot. Dotted horizontal and vertical lines at zero indicate no difference
between costs and effects of the two strategies. The broken lines
indicates a threshold (i.e., maximum willingness to pay) of $US 50’000
per QALY gained. The area to the right of the threshold line (i.e., the
point estimate and the respective part of the distribution) is considered
as cost-effective if the decision-maker’s maximum willingness to pay
per QALY is $US 50’000.
doi:10.1371/journal.pone.0000173.g001
Figure 2. Cost-effectiveness acceptability curves from the health care
(A) and societal (B) perspective. Vertical lines indicate the threshold
where genotypic antiretroviral resistance testing and treatment
optimization based on expert opinion have the same probability of
being cost-effective. At a higher willingness to pay per QALY gained
(e.g. at $US 50000/QALY) genotypic antiretroviral resistance testing has
a higher probability of being cost-effective than expert opinion alone.
doi:10.1371/journal.pone.0000173.g002
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where health insurance is often funded by employers. The
inclusion of GRT in health insurance plans not only leads to
a benefit to the patient but also to the employer by increasing job
productivity. Public health insurance coverage in the USA, on the
other hand, is tied to disability status. Patients with disability status
on public health insurance may also benefit from GRT based
treatment optimization, as a better health state may increase the
likelihood to return to work. Our results suggest that GRT
represents high value for money and should be offered to all
patients who can benefit from it.
SUPPORTING INFORMATION
Table S1 Transition probability matrix for HIV disease pro-
gression generated by pooling consecutive six-month observations
from patients on HAART enrolled in the SHCS between 1996–
2004. Numbers indicate observations, the likelihood is shown in
brackets. To calculate the posterior probability with a non-
informative prior, the number of observations in each cell with an
allowed transition is increased by one.
Found at: doi:10.1371/journal.pone.0000173.s001 (0.05 MB
DOC)
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